Benjamin Bielak: Thanks Tracy. I appreciate the question, Allen. Yes, certainly an exciting opportunity. As Tracy mentioned, the adjacencies that we have with us the platform we developed, we have a number of things in the pipeline. These are two of them. I’ll speak more specifically around the Data-as-a-Service because we’ve announced the pilot for the end of the year. iSpecimen is an interesting place in the overall market and the mix of data that we have with our partners, especially on the lab side is somewhat unique from an asset perspective and a depth perspective and an access perspective. So, the ability for our customers to understand this, even some customers in new spaces to be able to see the value and obviously the ability to get specimens after the fact for a lot of this data is also of interest.
And so your ability to package both what we do and as a specimen provider today and be able to extend that into leveraging the data we have both for our customers and obviously, for our suppliers as well is certainly of value and the interest is certainly there.
Allen Klee: Thank you.
Benjamin Bielak: The question €“ yes, on the market really quick. Marketplace as a service is a direct extension of the marketplace and the ability to — similar to what did, especially, having provide those things first and then be able to provide names suppliers as the marketplace continues to mature.
Allen Klee: That’s great. Thank you. One other question. Could you talk about your competitive position versus some of the alternatives out there? And to what degree existing customers could be spending more with you?
Tracy Curley: Sure. I’m going to do a brief answer and I’m going to turn that over to Eric, as my Chief Revenue Officer to answer that further. We’re the only company out there with the marketplace platform. And we’re going to use technology in order to be successful in our industry. Our position is not to hold inventory. We get our inventory directly from our supplier network. And that’s unique to this industry. It provides challenges, but also benefits to us from — capital investment if you will. Our competitors have done various things in order to get closer to the supplier and the source which Eric can talk a little bit more about compared to us. Eric, do you want to continue?
Eric Langlois: Sure. Yes. Our market is pretty unique. There is a wide range of competitors a lot of companies that are involved in it that do little pieces of different things. Some might do only inventory, some might do only perspective, some only do direct to patients, some do direct to clinical sites. So there’s a lot of variability in all of this. I think our major competitors what they’ve really done over the last several years is a, kind of, code in the market consolidation type approach. They’re really going after existing inventory and that’s one way to do it. And they’re certainly taking risk because they’re outlaying cash and operational assets to bring those things in-house to be able to deliver quickly. I think our approach is very different.
It’s very unique. We’re trying to aggregate as Tracy said aggregate access to a lot of different types of supply and a lot of different types of relationships that are involved in that both bank inventory and remnant. And I think our — still our claim to fame is really in the network effect. We’re able to do things in a much more bespoke manner than most of our competition. I think COVID evidenced that. Most of our competition could not really manage that, they couldn’t go through that, they couldn’t make the pivot that our customers required yet we could. That makes it hard in the interim until we get the marketplace effect that we’re aiming for and that Ben and his team are working on just because we end up getting a lot of hard requests.
